

Pack Insert
Date : 18OCT22
Date : 23NOV23*
Date : 28NOV23**
Date : 15FEB24***
Date : 02APR24****
Date : 05APR24*****
Date : 20JUN24*****
Date : 08AUG24*****

Malaysia Export
Version-7

Size : L- 310 x H-210 mm

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

Rx
Dienogest Tablets 2 mg
Evafact

For oral use only

Composition:
Each tablet contains:
Dienogest Ph. Eur. 2 mg

EXCIPIENTS
Lactose Monohydrate (200M and 30GR), Microcrystalline Cellulose (PH 101), Potato Starch, Crospovidone, Povidone (K25), Talc, Magnesium Stearate

PRODUCT DESCRIPTION
White to off-white, round, flat faced bevelled edge tablets debossed with "NC" on one side and "22" on other side.

PHARMACODYNAMICS
Pharmacotherapeutic group: progestogens; ATC code: G03DB08

Dienogest is a nortestosterone derivative with no androgenic but rather an antiandrogenic activity of approximately one third of that of cyproterone acetate. Dienogest binds to the progesterone receptor of the human uterus with only 10% of the relative affinity of progesterone. Despite its low affinity to the progesterone receptor, dienogest has a strong progestogenic effect in vivo. Dienogest has no significant androgenic, mineralocorticoid or glucocorticoid activity in vivo.

Dienogest acts on endometriosis by reducing the endogenous production of oestradiol and thereby suppresses the trophic effects of estradiol on both the eutopic and ectopic endometrium. When given continuously, dienogest leads to a hypoestrogenic, hypergestagenic endocrine environment causing initial decidualization of endometrial tissue followed by atrophy of endometriotic lesions.

PHARMACOKINETICS
Absorption
Orally administered dienogest is rapidly and almost completely absorbed. Peak serum concentrations of 47 ng/ml are reached at about 1.5 hours after single ingestion. Bioavailability is about 91%. The pharmacokinetics of dienogest are dose-proportional within the dose range of 1 - 8 mg.

Distribution
Dienogest is bound to serum albumin and does not bind to sex hormone binding globulin (SHBG) or corticoid binding globulin (CBG). 10 % of the total serum drug concentration is present as free steroid, 90 % is non-specifically bound to albumin.

The apparent volume of distribution (Vd/F) of dienogest is 40 L.

Biotransformation
Dienogest is completely metabolized by the known pathways of steroid metabolism, with the formation of endocrinologically mostly inactive metabolites. Based on in vitro and in vivo studies, CYP3A4 is the major enzyme involved in the metabolism of dienogest. The metabolites are excreted very quickly so that in plasma unchanged dienogest is the dominating fraction.

The metabolic clearance rate from serum Cl/F is 64 ml/min.

Elimination
Dienogest serum levels decrease in two phases. The terminal disposition phase is characterized by a half-life of approximately 9-10 hours. Dienogest is excreted in form of metabolites which are excreted at a urinary to faecal ratio of about 3:1 after oral administration of 0.1 mg/kg. The half-life of urinary metabolites excretion is 14 hours. Following oral administration approximately 86% of the dose administered is eliminated within 6 days, the bulk of

this amount excreted within the first 24 h, mostly with the urine.
Steady-state conditions
Pharmacokinetics of dienogest are not influenced by SHBG levels. Following daily ingestion drug serum levels increase about 1.24 fold reaching steady-state conditions after 4 days of treatment. The pharmacokinetics of dienogest after repeated administration of dienogest can be predicted from single dose pharmacokinetics.

Pharmacokinetics in Special Population

Dienogest has not been studied specifically in renally impaired subjects.

Dienogest has not been studied in subjects with hepatic impairment.

INDICATION
Treatment of endometriosis.

RECOMMENDED DOSAGE
Method of Administration

For oral use

Posology
The dosage of Evafact is one tablet daily without any break, taken preferably at the same time each day with some liquid as needed. The tablet can be taken with or without food.

Tablets must be taken continuously without regard to vaginal bleeding. When a pack is finished the next one should be started without interruption.

Treatment can be started on any day of the menstrual cycle.

Any hormonal contraception needs to be stopped prior to initiation of Evafact. If contraception is required, non-hormonal methods of contraception should be used (e.g., barrier method).

Management of missed tablets:
The efficacy of Evafact may be reduced in the event of missed tablets, vomiting and/or diarrhea (if occurring within 3-4 hours after tablet taking). In the event of one or more missed tablets, the woman should take one tablet only, as soon as she remembers, and should then continue the next day at her usual time. A tablet not absorbed due to vomiting or diarrhea should likewise be replaced by one tablet.

Additional information on special populations
Paediatric populations:
Evafact is not indicated in children prior to menarche. The safety and efficacy of Evafact was investigated in an uncontrolled clinical trial over 12 months in 111 adolescent women (12-<18) with clinically suspected or confirmed endometriosis.

The use of Evafact in adolescent patients over a treatment period of 12 months was associated with a mean decrease in Bone Mineral Density (BMD) in the lumbar spine of 1.2%. After cessation of treatment, BMD increased towards pre-treatment levels over a period of 6 months in a subset of patients with decreased BMD (mean change from baseline - 0.6%).

Loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. It is unknown if BMD decrease in this population will reduce peak bone mass and increase the risk for fracture in later life.

Therefore, the treating physician should weigh the benefits of Evafact against the possible risks of use in each individual adolescent patient.

Geriatric populations:
There is no relevant indication for use of Evafact in the Geriatric population.

Patients with hepatic impairment:
Evafact is contraindicated in patients with present or past severe hepatic disease.

Patients with renal impairment:
There are no data suggesting the need for a dosage adjustment in patients with renal impairment.

ROUTE OF ADMINISTRATION
Oral

CONTRAINDICATIONS
Dienogest should not be used in the presence of any of the conditions listed below, which are partially derived from information on other progesterone-only preparations. Should any of the conditions appear during the use of dienogest, treatment must be discontinued immediately.

- active venous thromboembolic disorder
- arterial and cardiovascular disease, past or present (e.g., myocardial infarction, cerebrovascular accident, ischemic heart disease)
- diabetes mellitus with vascular involvement
- presence or history of severe hepatic disease as long as liver function values have not returned to normal
- presence or history of liver tumours (benign or malignant)
- known or suspected sex hormone-dependent malignancies
- undiagnosed vaginal bleeding
- hypersensitivity to the active substance or to any of the excipients listed

WARNING AND PRECAUTIONS
As dienogest is a progestogen-only preparation it can be assumed that the special warnings and precautions for use of progestogen-only preparations are also valid for the use of dienogest although not all of the warnings and precautions are based on respective findings in the clinical studies with dienogest.

If any of the conditions/risk factors mentioned below is present or deteriorates, an individual risk-benefit analysis should be done before treatment with dienogest can be started or continued.

Serious uterine bleeding
Uterine bleeding, for example in women with adenomyosis uteri or uterine leiomyomata, may be aggravated with the use of dienogest. If bleeding is heavy and continuous over time, this may lead to anemia (severe in some cases). In the event of anemia, discontinuation of dienogest should be considered.

Changes in bleeding pattern
The majority of patients treated with dienogest experience changes in their menstrual bleeding pattern.

Circulatory disorders
From epidemiological studies there is little evidence for an association between progestogen-only preparations and an increased risk of myocardial infarction or cerebral thromboembolism. Rather, the risk of cardiovascular and cerebral events is related to increasing age, hypertension, and smoking. In women with hypertension the risk of stroke may be slightly enhanced by progestogen-only preparations.

Although not statistically significant, some studies indicate that there may be a slightly increased risk of venous thromboembolism (deep venous thrombosis, pulmonary embolism) associated with the use of progestogen-only preparations. Generally recognized risk factors for venous thromboembolism (VTE) include a positive personal or family history (VTE in a sibling or a parent at a relatively early age), age, obesity, prolonged immobilization, major surgery or major trauma. In case of long-term immobilization it is advisable to discontinue the use of dienogest (in the case of elective surgery at least four weeks in advance) and not to resume treatment until two weeks after complete remobilization.

The increased risk of thromboembolism in the puerperium must be considered.

Treatment should be stopped at once if there are symptoms of an arterial or venous thrombotic event or suspicion thereof.

Tumours
A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR= 1.24) of having breast cancer diagnosed in women who are currently using oral contraceptives (OCs), mainly using estrogen-progestogen preparations. The excess risk gradually disappears during the course of the 10 years after cessation of combined OC (COC) use. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. The risk of having breast cancer diagnosed in users of progestogen-only preparations is possibly of similar magnitude to that associated with COC. However, for progestogen-only preparations, the

evidence is based on much smaller populations of users and so is less conclusive than that for COCs. These studies do not provide evidence for causation. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in OC users, the biological effects of OCs or a combination of both. The breast cancers diagnosed in users of OCs tend to be less advanced clinically than the cancers diagnosed in those who have never used Ocs.

In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of hormonal substances such as the one contained in dienogest. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. A hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women taking dienogest.

Osteoporosis
Changes in bone mineral density (BMD)

The use of dienogest in adolescents (12 to <18 years) over a treatment period of 12 months was associated with a decrease in bone mineral density (BMD) in the lumbar spine (L2-L4). The mean relative change in BMD from baseline to the end of treatment (EOT) was - 1.2% with a range between -6% and 5% (IC 95%: 1.70% and -0.78%, n=103. Repeated measurement at 6 months after the EOT in a subgroup with decreased BMD values showed a trend towards recovery. (Mean relative change from baseline: -2.3% at EOT and -0.6% at 6 months after EOT with a range between -9% and 6% (IC 95%: -1.20% and 0.06% (n=60).

Loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. It is unknown if BMD decrease in this population will reduce peak bone mass and increase the risk for fracture in later life.

In patients who are at an increased risk of osteoporosis a careful risk-benefit assessment should be performed before starting dienogest because endogenous estrogen levels are moderately decreased during treatment with dienogest.

Adequate intake of calcium and Vitamin D, whether from the diet or from supplements, is important for bone health in women of all ages.

Other Conditions
Patients who have a history of depression should be carefully observed and the drug should be discontinued if the depression recurs to a serious degree.

Dienogest generally does not appear to affect blood pressure in normotensive women. However, if a sustained clinically significant hypertension develops during the use of dienogest, it is advisable to withdraw dienogest and treat the hypertension.

Recurrence of cholestatic jaundice and/or pruritus which occurred first during pregnancy or previous use of sex steroids necessitates the discontinuation of dienogest.

Dienogest may have a slight effect on peripheral insulin resistance and glucose tolerance. Diabetic women, especially those with a history of gestational diabetes mellitus, should be carefully observed while taking dienogest.

Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking dienogest. Pregnancies that occur among users of progestogen-only preparations used for contraception are more likely to be ectopic than are pregnancies among users of combined oral contraceptives. Therefore, in women with a history of extrauterine pregnancy or an impairment of tube function, the use of dienogest should be decided on only after carefully weighing the benefits against the risks. Persistent ovarian follicles (often referred to as functional ovarian cysts) may occur during the use of dienogest. Most of these follicles are asymptomatic, although some may be accompanied by pelvic pain.

Lactose
Each Evafact tablet contains 62.8 mg of lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption who are on a lactose-free diet should consider the amount contained in Evafact.

Black Colour

Paper : 40 gsm, ITC Print Paper
Outline & Cutting marks not to print
Artwork Code No. : IN234TE0MY
Back to Back Printing
2 Vertical & 3 Horizontal Folds

Font size: 7 pt
Font name: Times New Roman

Pack Insert
Date : 18OCT22
Date : 23NOV23*
Date : 28NOV23**
Date : 15FEB24***
Date : 02APR24****
Date : 05APR24*****
Date : 20JUN24*****
Date : 08AUG24*****
Malaysia Export
Version-7

Size : L- 310 x H-210 mm

Medical Examination A complete medical history should be taken and a physical and gynecological examination should be performed prior to the initiation or reinstitution of the use of dienogest, guided by the contraindications and warnings, and these should be repeated regularly during the use of dienogest. The frequency and nature of these assessments should be adapted to the individual woman but should generally include special reference to blood pressure, breasts, abdomen and pelvic organs, and should also include cervical cytology. INTERACTIONS WITH OTHER MEDICAMENTS Note: The prescribing information of concomitant medication should be consulted to identify potential interactions. Effects of other medicinal products on dienogest Progestogens including dienogest are metabolized mainly by the cytochrome P450 3A4 system (CYP3A4) located both in the intestinal mucosa and in the liver. Therefore, inducers or inhibitors of CYP3A4 may affect the progestogen drug metabolism. An increased clearance of sex hormones due to enzyme induction may reduce the therapeutic effect of dienogest and may result in undesirable effects e.g., changes in the uterine bleeding profile. A reduced clearance of sex hormones due to enzyme inhibition may increase the exposure to dienogest and may result in undesirable effects. - Substances increasing the clearance of sex hormones (diminished efficacy by enzyme-induction), e.g.: phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin and products containing St. John's wort (<i>Hypericum perforatum</i>) Enzyme induction can already be observed after a few days of treatment. Maximum enzyme induction is generally seen within a few weeks. After cessation of drug therapy enzyme induction may be sustained for about 4 weeks. The effect of the CYP 3A4 inducer rifampicin was studied in healthy postmenopausal women. Coadministration of rifampicin with estradiol valerate/dienogest tablets led to significant decreases in steady state concentrations and systemic exposures of dienogest and estradiol. The systemic exposure of dienogest and estradiol at steady state, measured by AUC(0-24h), were decreased by 83% and 44%, respectively. - <i>Substances with variable effects on the clearance of sex hormones:</i> When co-administered with sex hormones, many combinations of HIV protease inhibitors and nonnucleoside reverse transcriptase inhibitors, including combinations with HCV inhibitors can increase or decrease plasma concentrations of the progestin. The net effect of these changes may be clinically relevant in some cases. - <i>Substances decreasing the clearance of sex hormones (enzyme inhibitors)</i> Dienogest is a substrate of cytochrome P450 (CYP) 3A4. The clinical relevance of potential interactions with enzyme inhibitors remains Concomitant administration of strong CYP3A4 inhibitors can increase plasma concentrations of dienogest. Coadministration with the strong CYP3A4 enzyme inhibitor ketoconazole resulted in a 2.9-fold increase of AUC (0-24h) at steady state for dienogest. Concomitant administration of the moderate inhibitor erythromycin increased the AUC (0-24h) of dienogest at steady state by 1.6-fold. Effects of dienogest on other medicinal products Based on in vitro inhibition studies, a clinically relevant interaction of dienogest with the cytochrome P450 enzyme mediated metabolism of other medication is unlikely. Interaction with food A standardized high fat meal did not affect the bioavailability of dienogest.	Laboratory tests The use of progestogens may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins (e.g., corticosteroid binding globulin and lipid/lipoprotein fractions), parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range. PREGNANCY AND LACTATION Pregnancy There is limited data from the use of dienogest in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Dienogest must not be administered to pregnant women because there is no need to treat endometriosis during pregnancy. Lactation Treatment with dienogest during lactation is not recommended. It is unknown whether dienogest is excreted in human milk. Data in animals have shown excretion of dienogest in rat milk. A decision must be made whether to discontinue breast-feeding or to abstain from dienogest therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. Fertility Based on the available data, ovulation is inhibited in the majority of patients during treatment with dienogest. However, dienogest is not a contraceptive. If contraception is required a non-hormonal method should be used Based on available data, the menstrual cycle returns to normal within 2 months after cessation of treatment with dienogest. SIDE EFFECTS Presentation of undesirable effects is based on MedDRA. The most appropriate MedDRA term is used to describe a certain reaction and its synonyms and related conditions. Undesirable effects are more common during the first months after the start of treatment with dienogest, and subside with continued treatment. There may be changes in bleeding pattern, such as spotting, irregular bleeding or amenorrhea. The following undesirable effects have been reported in users of dienogest. The most frequently reported undesirable effects under treatment with dienogest are headache (9.0%), breast discomfort (5.4%), depressed mood (5.1 %) and acne (5.1 %). In addition, the majority of patients treated with dienogest experience changes in their menstrual bleeding pattern. Menstrual bleeding patterns were assessed systematically using patient diaries and were analyzed using the WHO 90 days reference period method. During the first 90 days of treatment with dienogest the following bleeding patterns were observed (n=290; 100%): Amenorrhea (1.7%), infrequent bleeding (27.2%), frequent bleeding (13.4%), irregular bleeding (35.2%), prolonged bleeding (38.3%), normal bleeding, i.e., none of the previous categories (19.7%). During the fourth reference period the following bleeding patterns were observed (n=149; 100%): Amenorrhea (28.2%), infrequent bleeding (24.2%), frequent bleeding (2.7%), irregular bleeding (21.5%), prolonged bleeding (4.0%), normal bleeding, i.e., none of the previous categories (22.8%). Changes in menstrual bleeding patterns were only occasionally reported as adverse event by the patients (See adverse event table). The frequencies of adverse drug reactions (ADRs) by MedDRA system organ classes (MedDRA SOCs) reported with dienogest are summarized in the table below. Within each frequency grouping, undesirable effects are presented in order of decreasing frequency.	Table 1, Adverse reactions table. <table><tr><th>System Organ Class (MedDRA)</th><th>Common</th><th>Uncommon</th></tr><tr><td>Blood and lymphatic system disorders</td><td></td><td>anemia</td></tr><tr><td>Metabolism and nutrition disorders</td><td>weight increase</td><td>weight decrease increased appetite</td></tr><tr><td>Psychiatric disorders</td><td>depressed mood sleep disorder nervousness loss of libido altered mood</td><td>anxiety depression mood swings</td></tr><tr><td>Nervous system disorders</td><td>headache migraine</td><td>autonomic nervous system imbalance disturbance in attention</td></tr><tr><td>Eye disorders</td><td></td><td>dry eye</td></tr><tr><td>Ear and labyrinth disorders</td><td></td><td>tinnitus</td></tr><tr><td>Cardiac disorders</td><td></td><td>unspecific circulatory systemv disorder palpitations</td></tr><tr><td>Vascular disorders</td><td></td><td>hypotension</td></tr><tr><td>Respiratory, thoracic and mediastinal disorders</td><td></td><td>dyspnoea</td></tr><tr><td>Gastrointestinal disorders</td><td>nausea abdominal pain flatulence abdominal distension vomiting</td><td>diarrhoea constipation abdominal discomfort gastrointestinal inflammation gingivitis</td></tr><tr><td>Skin and subcutaneous tissue disorders</td><td>acne alopecia</td><td>dry skin hyperhidrosis pruritus hirsutism onychoclasia dandruff dermatitis abnormal hair growth photosensitivity reaction pigmentation disorder</td></tr><tr><td>Musculoskeletal and connective tissue disorders</td><td>back pain</td><td>bone pain muscle spasms pain in extremity heaviness in extremities</td></tr><tr><td>Renal and urinary disorders</td><td></td><td>urinary tract infection</td></tr><tr><td>Reproductive system and breast disorders</td><td>breast discomfort ovarian cyst, hot flushes uterine / vaginal bleeding including spotting</td><td>vaginal candidiasis vulvovaginal dryness genital discharge pelvic pain atrophic vulvovaginitis breast mass fibrocystic breast disease breast induration</td></tr><tr><td>General disorders and administration site conditions</td><td>asthenic conditions irritability</td><td>Oedema</td></tr></table>	System Organ Class (MedDRA)	Common	Uncommon	Blood and lymphatic system disorders		anemia	Metabolism and nutrition disorders	weight increase	weight decrease increased appetite	Psychiatric disorders	depressed mood sleep disorder nervousness loss of libido altered mood	anxiety depression mood swings	Nervous system disorders	headache migraine	autonomic nervous system imbalance disturbance in attention	Eye disorders		dry eye	Ear and labyrinth disorders		tinnitus	Cardiac disorders		unspecific circulatory systemv disorder palpitations	Vascular disorders		hypotension	Respiratory, thoracic and mediastinal disorders		dyspnoea	Gastrointestinal disorders	nausea abdominal pain flatulence abdominal distension vomiting	diarrhoea constipation abdominal discomfort gastrointestinal inflammation gingivitis	Skin and subcutaneous tissue disorders	acne alopecia	dry skin hyperhidrosis pruritus hirsutism onychoclasia dandruff dermatitis abnormal hair growth photosensitivity reaction pigmentation disorder	Musculoskeletal and connective tissue disorders	back pain	bone pain muscle spasms pain in extremity heaviness in extremities	Renal and urinary disorders		urinary tract infection	Reproductive system and breast disorders	breast discomfort ovarian cyst, hot flushes uterine / vaginal bleeding including spotting	vaginal candidiasis vulvovaginal dryness genital discharge pelvic pain atrophic vulvovaginitis breast mass fibrocystic breast disease breast induration	General disorders and administration site conditions	asthenic conditions irritability	Oedema	PACKAGING AVAILABLE 14 tablets are packed into a blister strip comprising of printed aluminum foil and green rigid PVC-PVDC. 2 blister strips are packed into an outer box with a product leaflet. Pack size: 2 x 14's tablets BSV PRODUCT OWNER Bharat Serums and Vaccines Limited 3rd Floor, Liberty Tower, Plot No. K-10, Behind Reliable Plaza, Kalwa Industrial Estate, Airoli, Navi Mumbai - 400708, India MANUFACTURER Naari Pharma Private Limited Block-1, Plot No. 14-16 & 55-57, Sector-5, IIE, Pantnagar, Rudrapur, Dist. Udham Singh Nagar, Uttarakhand, 263153, India. PRODUCT REGISTRATION HOLDER BSV Bioscience Malaysia Sdn. Bhd. 3, Jalan 19/1, 46300 Petaling Jaya, Selangor, Malaysia. LEAFLET REVISION DATE October 2024
System Organ Class (MedDRA)	Common	Uncommon																																																	
Blood and lymphatic system disorders		anemia																																																	
Metabolism and nutrition disorders	weight increase	weight decrease increased appetite																																																	
Psychiatric disorders	depressed mood sleep disorder nervousness loss of libido altered mood	anxiety depression mood swings																																																	
Nervous system disorders	headache migraine	autonomic nervous system imbalance disturbance in attention																																																	
Eye disorders		dry eye																																																	
Ear and labyrinth disorders		tinnitus																																																	
Cardiac disorders		unspecific circulatory systemv disorder palpitations																																																	
Vascular disorders		hypotension																																																	
Respiratory, thoracic and mediastinal disorders		dyspnoea																																																	
Gastrointestinal disorders	nausea abdominal pain flatulence abdominal distension vomiting	diarrhoea constipation abdominal discomfort gastrointestinal inflammation gingivitis																																																	
Skin and subcutaneous tissue disorders	acne alopecia	dry skin hyperhidrosis pruritus hirsutism onychoclasia dandruff dermatitis abnormal hair growth photosensitivity reaction pigmentation disorder																																																	
Musculoskeletal and connective tissue disorders	back pain	bone pain muscle spasms pain in extremity heaviness in extremities																																																	
Renal and urinary disorders		urinary tract infection																																																	
Reproductive system and breast disorders	breast discomfort ovarian cyst, hot flushes uterine / vaginal bleeding including spotting	vaginal candidiasis vulvovaginal dryness genital discharge pelvic pain atrophic vulvovaginitis breast mass fibrocystic breast disease breast induration																																																	
General disorders and administration site conditions	asthenic conditions irritability	Oedema																																																	

Black Colour

Paper : 40 gsm, ITC Print Paper
Outline & Cutting marks not to print
Artwork Code No. : IN234TE0MY
Back to Back Printing
2 Vertical & 3 Horizontal Folds

Font size: 7 pt
Font name: Times New Roman